Phase III Study of Idelalisib /Rituximab for Relapsed Chronic Lymphocytic Leukemia
Dr. Jeff Sharman analysis of a phase 3 study of idelalisib plus rituximab for relapsed chronic lymphocytic leukemia: efficacy analysis in patient subpopulations with Del(17p) and other adverse prognos...
Author: feeds
Added: 04/15/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Rituxan | Study